Cart
sales@molnova.com
Trazpiroben
CAS No. 1352993-39-5
Trazpiroben( —— )
Catalog No. M35067 CAS No. 1352993-39-5
Trazpiroben (TAK-906) is a selective dopamine D2/D3 receptor antagonist utilized in gastroparesis research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTrazpiroben
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrazpiroben (TAK-906) is a selective dopamine D2/D3 receptor antagonist utilized in gastroparesis research.
-
DescriptionTrazpiroben (TAK-906) is a dopamine D2/D3 receptor antagonist used for chronic research of moderate-to-severe gastroparesis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1352993-39-5
-
Formula Weight517.66
-
Molecular FormulaC31H39N3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)C1=CC=CC(=C1)CN2C(=O)C3(N(C2)C4CCCCC4)CCN(CCCC(=O)C=5C=CC=CC5)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kuo B, Scimia C, Dukes G, Zhang W, Gupta S, Chen C, Chuang E, Camilleri M. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2?/D3?receptor antagonist, in patients with gastroparesis. Aliment Ph?
molnova catalog
related products
-
A 77636 hydrochlorid...
A-77636 hydrochloride is a potent, orally active, selective and long acting dopamine D1 receptor agonist (pKi=7.40; Ki=39.8 nM).
-
5-Benzyloxygramine
5-Benzyloxygramine blocks the Dopamin receptors and antagonizes the effects of 5-HT on the rat uterus and the rabbit ear.
-
Alpha-Methyldopa Ses...
Alpha-Methyldopa Sesquihydrate is a DOPA decarboxylase inhibitor and indirect α2-adrenergic receptor agonist used to treat hypertension.?It inhibits the sympathetic nervous system decreases production of dopamine norepinephrine and epinephrine and exhibits NO-dependent sedative activity.
